Geron (NASDAQ: GERN) Q3 2024 Earnings Call Nov 07, 2024, 8:00 a.m. ET Hello, and welcome to the Geron Corporation ...

Vera Therapeutics appointed Amgen and Seagen alum Matt Skelton as EVP of commercial. Frank Lane was appointed SVP and head of ...

Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course ...

Geron Corporation's Rytelo gains FDA approval for MDS treatment, with promising sales and positive analyst outlook. Click ...

Q3 2024 Earnings Call Transcript November 7, 2024 Geron Corporation beats earnings expectations. Reported EPS is $-0.04, ...

Shares of Geron Co. (NASDAQ:GERN – Get Free Report) have been assigned an average recommendation of “Buy” from the eleven ...

Geron (GERN) stock gains as the company reported strong Q3 earnings and secured a $375M funding deal with Royalty Pharma and ...

Analyst Faisal Khurshid from Leerink Partners reiterated a Buy rating on Geron (GERN – Research Report) and keeping the price target at ...

H.C. Wainwright has recently initiated Geron Corp (GERN) stock to Buy rating, as announced on November 5, 2024, according to Finviz. Earlier, on October 16, 2024, Scotiabank had initiated the stock to ...

Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course ...

Geron Corporation ( (GERN) ) has released its Q3 earnings. Here is a breakdown of the information Geron Corporation presented to its investors.

Financially distressed building owners in New York City’s outer boroughs and Long Island are filing untenable bankruptcy ...